| Drug Name: | Lidocaine Hydrochloride and Dextrose |
| Manufacturer: | B. Braun Medical Inc. |
| Other Info: | B. Braun Medical Inc.Irvine, CA USA 92614-5895In Canada, distributed by:B. Braun Medical Inc.Scarborough, Ontario M1H 2W4©2004 B. Braun Medical Inc.Y36-002-493 |
| Clinical Trials: | |
Constant monitoring with an electrocardiograph is essential to the proper administration of lidocaine hydrochloride intravenously.
Signs of excessive depression of cardiac conductivity, such as prolongation of the PR interval, widening of the QRS interval or the appearance or aggravation of arrhythmias, should be followed by prompt cessation of the intravenous infusion of this agent.
It is mandatory to have emergency resuscitative equipment and drugs immediately available to manage adverse reactions involving cardiovascular, respiratory, or central nervous systems.
Occasional acceleration of ventricular rate may occur when lidocaine hydrochloride is administered to patients with atrial fibrillation.
Evidence for proper usage in pediatric patients is limited.Because dosages of this drug are titrated to response (see DOSAGE AND ADMINISTRATION), no additives should be made to Lidocaine Hydrochloride and 5% Dextrose Injection USP.